AR-13503
Modify Date: 2024-01-19 16:30:08
AR-13503 structure
|
Common Name | AR-13503 | ||
|---|---|---|---|---|
| CAS Number | 1254032-16-0 | Molecular Weight | 321.37 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C19H19N3O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of AR-13503AR-13503 a ROCK/PKC inhibitor, inhibiting angiogenesis and enhancing retinal pigment epithelium (RPE) permeability. AR-13503 also inhibits the formation of aberrant neovascularization (NV) in oxygen-induced retinopathy (OIR) model in mice[1][2]. |
| Name | AR-13503 |
|---|
| Description | AR-13503 a ROCK/PKC inhibitor, inhibiting angiogenesis and enhancing retinal pigment epithelium (RPE) permeability. AR-13503 also inhibits the formation of aberrant neovascularization (NV) in oxygen-induced retinopathy (OIR) model in mice[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | AR-13503 (16 小时) 抑制人脐静脉内皮细胞 (HUVEC) 管的形成，IC50 为 21 nM[1]。 AR-13503 (400 nM; 5 天) 以剂量依赖的方式减少脉络膜的发芽面积[1]。 AR-13503 (400 nM; 2 周) 以剂量依赖的方式增强猪主要 RPE 屏障功能[1]。 |
| In Vivo | AR-13503 (1.25 mg/kg；腹腔注射；每天 1 次，共 5 天) 与 Aflibercept (HY-108801) 有协同作用，显著降低了异常新生血管 (NV) 形成[1]。 Animal Model: Oxygen-induced retinopathy (OIR) mice model (C57BL/6; 7-days-old)[1] Dosage: 1.25 mg/kg Administration: Intraperitoneal injection; once daily for 5 days Result: The combination group had a greater (~75%) reduction in NV than Aflibercept alone (~55%). |
| References |
| Molecular Formula | C19H19N3O2 |
|---|---|
| Molecular Weight | 321.37 |